This finding corresponds to a previous study showing that higher levels of OXPHOS in tumor and peripheral blood-derived CD8+ T cells correlate with ICI resistance35 and to our previous study devising an OXPHOS signature associated with the poor response of ICI-treated patients.36 The gene discussed is CD8A; the disease is neoplasm.